Glucagon by Fresenius Kabi USA, LLC / Fresenius Kabi USA, LLC GLUCAGON- glucagon kit

Glucagon by

Drug Labeling and Warnings

Glucagon by is a Prescription medication manufactured, distributed, or labeled by Fresenius Kabi USA, LLC , Fresenius Kabi USA, LLC. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

Important Administration Instructions for Using the Glucagon Emergency Kit for Low Blood Sugar to Treat

Severe Hypoglycemia (2.1)

Dosage in Adults for Using Glucagon for Injection Diagnostic Kit and Glucagon for Injection Single-Dose Vial as a Diagnostic Aid (2.4)

DOSAGE FORMS AND STRENGTHS

For Injection (3):

CONTRAINDICATIONS

WARNINGS AND PRECAUTIONS

ADVERSE REACTIONS

Most common adverse reactions ( >5% or greater incidence): Injection site swelling, injection site erythema, vomiting, nausea, decreased blood pressure, asthenia, headache, dizziness, pallor, diarrhea, and somnolence. (6)

To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. (6)

DRUG INTERACTIONS

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 9/2019

  • Table of Contents

    FULL PRESCRIBING INFORMATION: CONTENTS*

    1 INDICATIONS AND USAGE

    1.1 Severe Hypoglycemia

    1.2 Diagnostic Aid

    2 DOSAGE AND ADMINISTRATION

    2.1 Important Administration Instructions for Using the Glucagon Emergency Kit for Low Blood Sugar to Treat Severe Hypoglycemia

    2.2 Dosage in Adults and Pediatric Patients for Using the Glucagon Emergency Kit for Low Blood Sugar to Treat Severe Hypoglycemia

    2.3 Important Administration Instruction for Using Glucagon for Injection Diagnostic Kit and Glucagon for Injection Single-Dose Vial as a Diagnostic Aid

    2.4 Dosage in Adults for Using Glucagon for Injection Diagnostic Kit and Glucagon for Injection Single-Dose Vial as a Diagnostic Aid

    3 DOSAGE FORMS AND STRENGTHS

    4 CONTRAINDICATIONS

    5 WARNINGS AND PRECAUTIONS

    5.1 Catecholamine Release in Patients with Pheochromocytoma

    5.2 Hypoglycemia in Patients with Insulinoma

    5.3 Hypersensitivity and Allergic Reactions

    5.4 Lack of Efficacy in Patients with Decreased Hepatic Glycogen

    5.5 Necrolytic Migratory Erythema

    5.6 Hyperglycemia in Patients with Diabetes Mellitus when Used as a Diagnostic Aid

    5.7 Blood Pressure and Heart Rate Increase in Patients with Cardiac Disease when Used as a Diagnostic Aid

    5.8 Hypoglycemia in Patients with Glucagonoma

    6 ADVERSE REACTIONS

    6.1 Clinical Studies Experience

    6.2 Postmarketing Experience

    7 DRUG INTERACTIONS

    7.1

    8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    8.2 Lactation

    8.4 Pediatric Use

    10 OVERDOSAGE

    11 DESCRIPTION

    12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    12.2 Pharmacodynamics

    12.3 Pharmacokinetics

    13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    16 HOW SUPPLIED/STORAGE AND HANDLING

    16.1 How Supplied

    16.2 Recommended Storage

    17 PATIENT COUNSELING INFORMATION

  • * Sections or subsections omitted from the full prescribing information are not listed.
  • 1 INDICATIONS AND USAGE

    1.1 Severe Hypoglycemia

    Glucagon for Injection is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes.

    1.2 Diagnostic Aid

    Glucagon for Injection is indicated as a diagnostic aid for use during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients.

  • 2 DOSAGE AND ADMINISTRATION

    2.1 Important Administration Instructions for Using the Glucagon Emergency Kit for Low Blood Sugar to Treat Severe Hypoglycemia

    Glucagon for Injection is for subcutaneous, intramuscular, or intravenous injection. Administer intravenously ONLY under medical supervision.

    Instruct patients and their caregivers on the signs and symptoms of severe hypoglycemia. Because severe hypoglycemia requires the help of others to recover, instruct the patient to inform those around them about Glucagon for Injection and its Instructions for Use. Administer Glucagon for Injection as soon as possible when severe hypoglycemia is recognized.

    Instruct the patient or caregiver to read the Instructions for Use at the time they receive a prescription for Glucagon for Injection. Emphasize the following instructions to the patient or caregiver:

    • Using the supplied prefilled syringe, carefully insert the needle through the rubber stopper of the vial containing Glucagon for Injection powder and inject all the liquid from the syringe into the vial.
    • Shake the vial gently until the powder is completely dissolved and no particles remain in the fluid. The reconstituted solution should be clear and colorless. Inspect visually for particulate matter and discoloration. If the resulting solution is cloudy or contains particulate matter do not use.
    • The reconstituted solution is 1 mg per mL glucagon.
    • Immediately after reconstitution, inject the solution subcutaneously or intramuscularly in the upper arm, thigh, or buttocks. In addition, healthcare providers may administer intravenously.
    • Call for emergency assistance immediately after administering the dose.
    • When the patient has responded to the treatment and is able to swallow, give oral carbohydrates to restore the liver glycogen and prevent recurrence of hypoglycemia.
    • Discard any unused portion.

    2.2 Dosage in Adults and Pediatric Patients for Using the Glucagon Emergency Kit for Low Blood Sugar to Treat Severe Hypoglycemia

    Adults and Pediatric Patients Weighing More Than 25 kg or for Pediatric Patients with Unknown Weight 6 Years and Older

    • The recommended dosage is 1 mg (1 mL) injected subcutaneously or intramuscularly into the upper arm, thigh, or buttocks, or intravenously.
    • If there has been no response after 15 minutes, an additional 1 mg dose (1 mL) of Glucagon for Injection may be administered using a new kit while waiting for emergency assistance.

    Pediatric Patients Weighing Less Than 25 kg or for Pediatric Patients with Unknown Weight Less Than 6 Years of Age

    • The recommended dosage is 0.5 mg (0.5 mL) injected subcutaneously or intramuscularly into the upper arm, thigh, or buttocks, or intravenously.
    • If there has been no response after 15 minutes, an additional 0.5 mg dose (0.5 mL) of Glucagon for Injection may be administered using a new kit while waiting for emergency assistance.

    2.3 Important Administration Instruction for Using Glucagon for Injection Diagnostic Kit and Glucagon for Injection Single-Dose Vial as a Diagnostic Aid

    • Reconstitute Glucagon for Injection with 1 mL of Sterile Water for Injection. Using a syringe, withdraw all of the Sterile Water for Injection (if supplied) or 1 mL Sterile Water for Injection and inject into the Glucagon for Injection vial.
    • Shake the vial gently until the powder is completely dissolved and no particles remain in the fluid. The reconstituted fluid should be clear and colorless. Inspect visually for particulate matter and discoloration. If the resulting solution is cloudy or contains particulate matter do not use.
    • The reconstituted solution is 1 mg per mL glucagon.
    • Immediately after reconstitution, inject the solution intravenously or intramuscularly into upper arm, thigh, or buttocks.
    • Discard any unused portion.
    • After the end of the diagnostic procedure, give oral carbohydrates to patients who have been fasting, if this is compatible with the diagnostic procedure.

    2.4 Dosage in Adults for Using Glucagon for Injection Diagnostic Kit and Glucagon for Injection Single-Dose Vial as a Diagnostic Aid

    • The recommended diagnostic dose for relaxation of the stomach, duodenal bulb, duodenum, and small bowel is 0.2 mg to 0.5 mg administered intravenously or 1 mg administered intramuscularly; the recommended dose to relax the colon is 0.5 mg to 0.75 mg administered intravenously or 1 mg to 2 mg administered intramuscularly [see Clinical Pharmacology (12.2)].
    • The onset of action after an injection will depend on the organ under examination and route of administration [see Clinical Pharmacology (12.2)].
  • 3 DOSAGE FORMS AND STRENGTHS

    Glucagon for Injection is a white lyophilized powder supplied as follows:

    Treatment of Severe Hypoglycemia

    Use as a Diagnostic Aid

  • 4 CONTRAINDICATIONS

    Glucagon for Injection is contraindicated in patients with:

  • 5 WARNINGS AND PRECAUTIONS

    5.1 Catecholamine Release in Patients with Pheochromocytoma

    Glucagon for Injection is contraindicated in patients with pheochromocytoma because glucagon may stimulate the release of catecholamines from the tumor [see Contraindications (4)]. If the patient develops a dramatic increase in blood pressure and a previously undiagnosed pheochromocytoma is suspected, 5 to 10 mg of phentolamine mesylate, administered intravenously, has been shown to be effective in lowering blood pressure.

    5.2 Hypoglycemia in Patients with Insulinoma

    In patients with insulinoma, administration of glucagon may produce an initial increase in blood glucose; however, Glucagon for Injection administration may directly or indirectly (through an initial rise in blood glucose) stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. Glucagon for Injection is contraindicated in patients with insulinoma [see Contraindications (4)]. If a patient develops symptoms of hypoglycemia after a dose of Glucagon for Injection, give glucose orally or intravenously.

    5.3 Hypersensitivity and Allergic Reactions

    Allergic reactions have been reported with glucagon, these include generalized rash, and in some cases anaphylactic shock with breathing difficulties and hypotension. Glucagon for Injection is contraindicated in patients with a prior hypersensitivity reaction [see Contraindications (4)].

    5.4 Lack of Efficacy in Patients with Decreased Hepatic Glycogen

    Glucagon for Injection is effective in treating hypoglycemia only if sufficient hepatic glycogen is present. Patients in states of starvation, with adrenal insufficiency or chronic hypoglycemia may not have adequate levels of hepatic glycogen for Glucagon for Injection administration to be effective. Patients with these conditions should be treated with glucose.

    5.5 Necrolytic Migratory Erythema

    Necrolytic migratory erythema (NME), a skin rash commonly associated with glucagonomas (glucagonproducing tumors) and characterized by scaly, pruritic erythematous plaques, bullae, and erosions, has been reported postmarketing following continuous glucagon infusion. NME lesions may affect the face, groin, perineum and legs or be more widespread. In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. Should NME occur, consider whether the benefits of continuous glucagon infusion outweigh the risks.

    5.6 Hyperglycemia in Patients with Diabetes Mellitus when Used as a Diagnostic Aid

    Treatment with Glucagon for Injection in patients with diabetes mellitus may cause hyperglycemia. Monitor diabetic patients for changes in blood glucose levels during treatment and treat if indicated.

    5.7 Blood Pressure and Heart Rate Increase in Patients with Cardiac Disease when Used as a Diagnostic Aid

    Glucagon for Injection may increase myocardial oxygen demand, blood pressure, and pulse rate which may be life-threatening in patients with cardiac disease. Cardiac monitoring is recommended in patients with cardiac disease during use of Glucagon for Injection as a diagnostic aid, and an increase in blood pressure and pulse rate may require therapy.

    5.8 Hypoglycemia in Patients with Glucagonoma

    Glucagon administered to patients with glucagonoma may cause secondary hypoglycemia. Glucagon for Injection is contraindicated in patients with glucagonoma when used as a diagnostic aid [see Contraindications (4)]. Test patients suspected of having glucagonoma for blood levels of glucagon prior to treatment, and monitor for changes in blood glucose levels during treatment. If a patient develops symptoms of hypoglycemia after a dose of Glucagon for Injection, give glucose orally or intravenously.

  • 6 ADVERSE REACTIONS

    The following important adverse reactions are described below and elsewhere in the labeling:

    6.1 Clinical Studies Experience

    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the rates in clinical trials of another drug and may not reflect the rates observed in practice.

    In a randomized single-blind clinical study of Glucagon for Injection, 29 healthy subjects received a single dose of 1 mg Glucagon for Injection intramuscularly. Table 1 shows the most common adverse reactions that were not present at baseline and occurred in at least 5% of patients.

    Table 1: Adverse Reactions Occurring in ≥ 5% of Healthy Subjects Who Received Glucagon for Injection Intramuscularly
    Glucagon for Injection
    (N=29)
    % of Patients
    Nausea 17
    Vomiting 7

    In a randomized, single-blind clinical study of Glucagon for Injection, 31 healthy subjects received a single dose of 1 mg Glucagon for Injection subcutaneously. Table 2 shows the most common adverse reactions that were not present at baseline and occurred in at least 5% of patients. (2.1)].

    Table 2: Adverse Reactions Occurring ≥5% in Healthy Subjects Who Received Glucagon for Injection Subcutaneously
    Glucagon for Injection
    (N=31)
    % of Patients
    Injection site swelling 58
    Injection site erythema 55
    Vomiting 36
    Nausea 32
    Decreased blood pressure 23
    Asthenia 23
    Headache 13
    Dizziness 10
    Pallor 10
    Diarrhea 7
    Somnolence 7

    Other Adverse Reactions

    Hypertension and tachycardia have occurred with glucagon treatment.

    6.2 Postmarketing Experience

    Additional adverse reactions have been identified during post-approval use of glucagon. Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

    • hypoglycemia and hypoglycemic coma. Patients taking indomethacin may be more likely to experience hypoglycemia following glucagon administration [see Drug Interactions (7)].
    • Necrolytic migratory erythema (NME) cases have been reported postmarketing in patients receiving continuous infusion of glucagon.
  • 7 DRUG INTERACTIONS

    7.1

    Table 3: Clinically Significant Drug Interactions with Glucagon for Injection
    Beta-Blockers
    Clinical Impact:Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given Glucagon for Injection.
    Intervention:The increase in blood pressure and heart rate may require therapy in patients with coronary artery disease.
    Indomethacin
    Clinical Impact:In patients taking indomethacin, Glucagon for Injection may lose its ability to raise blood glucose or may even produce hypoglycemia.
    Intervention:Monitor blood glucose levels during glucagon treatment of patients taking indomethacin.
    Anticholinergic Drugs
    Clinical Impact:The concomitant use of anticholinergic drugs and Glucagon for Injection increases the risk of gastrointestinal adverse reactions due to additive effects on inhibition of gastrointestinal motility.
    Intervention:Concomitant use of anticholinergic drugs with Glucagon for Injection for use as a diagnostic aid is not recommended.
    Warfarin
    Clinical Impact:Glucagon for Injection may increase the anticoagulant effect of warfarin.
    Intervention:Monitor patients for unusual bruising or bleeding, as adjustments in warfarin dosage may be required.
    Insulin
    Clinical Impact:Insulin acts antagonistically to glucagon.
    Intervention:Monitor blood glucose when Glucagon for Injection is used as a diagnostic aid in patients receiving insulin.
  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk Summary

    Available data from case reports and a small number of observational studies with glucagon use in pregnant women over decades of use have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Multiple small studies have demonstrated a lack of transfer of pancreatic glucagon across the human placental barrier during early gestation. In rat and rabbit reproduction studies, no embryofetal toxicity was observed with glucagon administered by injection during the period of organogenesis at doses representing up to 100 and 200 times the human dose, respectively, based on body surface area (mg/m2) (see Data).

    The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively.

    Data

    Animal Data

    In rats and rabbits given glucagon by injection at doses of 0.4, 2.0, and 10 mg/kg (up to 100 and 200 times the human dose based on mg/m2 for rats and rabbits, respectively) there was no evidence of increased malformations or embryofetal lethality.

    8.2 Lactation

    Risk Summary

    There is no information available on the presence of glucagon in human or animal milk, the effects of glucagon on the breastfed child or the effects of glucagon on milk production. However, glucagon is a peptide and would be expected to be broken down to its constituent amino acids in the infant's digestive tract and is therefore, unlikely to cause harm to an exposed infant.

    8.4 Pediatric Use

    The safety and effectiveness of Glucagon for Injection for the treatment of severe hypoglycemia in pediatric patients with diabetes have been established.

    Safety and effectiveness for use as a diagnostic aid during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in pediatric patients have not been established.

  • 10 OVERDOSAGE

    If overdosage occurs, the patient may experience nausea, vomiting, inhibition of GI tract motility, increase in blood pressure and pulse rate. In case of suspected overdosing, the serum potassium may decrease and should be monitored and corrected if needed. If the patient develops a dramatic increase in blood pressure, phentolamine mesylate has been shown to be effective in lowering blood pressure for the short time that control would be needed.

  • 11 DESCRIPTION

    Glucagon is an antihypoglycemic agent and a gastrointestinal motility inhibitor. It is produced by solid phase peptide synthesis. The chemical structure of the glucagon is identical to human glucagon. Glucagon is a single-chain polypeptide containing 29 amino acid residues. The structure of glucagon is:

    Figure
    Molecular Formula = C153H225N43O49S                               Molecular Weight = 3483

    Glucagon for Injection is a sterile, lyophilized white powder in a 3 mL vial for subcutaneous, intramuscular or intravenous use. The reconstituted solution contains glucagon as hydrochloride 1 mg per mL and lactose monohydrate (107 mg). Glucagon for Injection is supplied at pH 2.5 to 3.5 and is soluble in water.

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Glucagon increases blood glucose concentration by activating hepatic glucagon receptors, thereby stimulating glycogen breakdown and release of glucose from the liver. Hepatic stores of glycogen are necessary for glucagon to produce an antihypoglycemic effect. Extrahepatic effects of glucagon include relaxation of the smooth muscle of the stomach, duodenum, small bowel, and colon.

    12.2 Pharmacodynamics

    Treatment of Severe Hypoglycemia

    Blood glucose concentration rises within 10 minutes of injection and maximal concentrations are attained at approximately 30 minutes after injection (see Figure 1). The duration of hyperglycemic action after intravenous or intramuscular injection is 60 to 90 minutes.

    Figure 1. Recovery from Insulin Induced Hypoglycemia (mean blood glucose) After Intramuscular Injection of 1 mg of Another Glucagon for Injection Product in Type I Diabetic Men

    Figure

    Diagnostic Aid

    Table 4: Pharmacodynamic Properties of Another Glucagon for Injection Product For Intravenous Route

    aDose is determined based on the length of the procedure.

    Route of AdministrationDoseaTime of Maximal
    Glucose
    Concentration    		Time of Onset of
    Action for GI Smooth Muscle Relaxation    		Duration of
    Smooth Muscle Relaxation
    Intravenous 0.25 to 0.5 mg 5 to 20 minutes 45 seconds 9 to 17 minutes
    Table 5 Pharmacodynamic Properties of Another Glucagon for Injection Product For Intramuscular Route

    aDose is determined based on the length of the procedure.

    Route of AdministrationDoseaTime of Maximal
    Glucose
    Concentration    		Time of Onset of
    Action for GI Smooth Muscle Relaxation    		Duration of
    Smooth Muscle Relaxation
    Intramuscular 1 mg 30 minutes 8 to 10 minutes 12 to 27 minutes
    2 mg 30 minutes 4 to 7 minutes 21 to 32 minutes

    In a study in healthy subjects, a subcutaneous dose of 1 mg Glucagon for Injection resulted on average a peak blood glucose concentration of 79.3 mg/dL with a median time of 50 minutes after injection.

    12.3 Pharmacokinetics

    Absorption

    Following subcutaneous administration of Glucagon for Injection, the median time to reach the maximum baseline uncorrected plasma glucagon concentrations of 3533 pg/mL was approximately 10 to 13 minutes after dosing Following intramuscular administration of 1 mg dose, the maximum baseline uncorrected plasma glucagon concentrations of 3391 pg/mL were attained approximately 10 minutes after dosing.

    Elimination

    The mean apparent half-life of glucagon was about 42 minutes after subcutaneous administration. The mean apparent half-life of glucagon was 26 minutes after intramuscular administration.

    Metabolism

    Glucagon is degraded in the liver, kidney, and plasma.

  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    Carcinogenesis

    Long term studies in animals to evaluate carcinogenic potential have not been performed.

    Mutagenesis

    Synthetic glucagon was negative in the bacterial reverse mutation assay (Ames test). The clastogenic potential of synthetic glucagon in the Chinese Hamster Ovary (CHO) assay was positive in the absence of metabolic activation. Doses of 100 and 200 mg/kg of glucagon of both pancreatic and recombinant origins gave slightly higher incidences of micronucleus formation in male mice but there was no effect in females. The weight of evidence indicates that synthetic and recombinant glucagon are not different and do not pose a genotoxic risk to humans.

    Impairment of Fertility

    Glucagon was not tested in animal fertility studies. Studies in rats have shown that pancreatic glucagon does not cause impaired fertility.

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    16.1 How Supplied

    Glucagon for Injection is supplied as a sterile, lyophilized white powder available as follows:

    PresentationNDCStrengthDescription
    Treatment of Severe Hypoglycemia
    Glucagon Emergency Kit for Low Blood Sugar 63323-582-82 1 mg per vial 1 mL single-dose vial of Glucagon for Injection with 1 mL single-dose syringe of Sterile Water for
    Injection, USP for reconstitution
    Use as a Diagnostic Aid
    10 Single-dose vials 63323-596-13 1 mg per vial 1 mL single-dose vial of Glucagon for Injection
    Diagnostic Kit 63323-593-03 1 mg per vial 1 mL single-dose vial of Glucagon for Injection with
    1 mL single-dose vial of Sterile Water for Injection,
    USP for reconstitution

    16.2 Recommended Storage

    Before Reconstitution

    The package containing Glucagon for Injection vials may be stored up to 24 months at 20° to 25° C (68° to 77° F) [see USP Controlled Room Temperature] prior to reconstitution. Do not freeze. Keep in the original package to protect from light.

    After Reconstitution

    Use reconstituted glucagon solution immediately. Discard any unused portion [see Dosage and Administration (2.3)].

  • 17 PATIENT COUNSELING INFORMATION

    Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).

    Recognition of Severe Hypoglycemia

    Inform patient and family members or caregivers on how to recognize the signs and symptoms of severe hypoglycemia and the risks of prolonged hypoglycemia.

    Administration

    Review the Patient Information and Instructions for Use with the patient and family members or caregivers.

    Serious Hypersensitivity

    Inform patients that allergic reactions can occur with Glucagon for Injection. Advise patients to seek immediate medical attention if they experience any symptoms of serious hypersensitivity reactions [see Warnings and Precautions (5.3)].

  • PATIENT PACKAGE INSERT

    This Patient Information has been approved by the U.S. Food and Drug Administration

    Approved: 09/2019

    PATIENT INFORMATION
    Glucagon (GLOO-ka-gon)
    for injection, for subcutaneous, intramuscular or
    intravenous use
    What is Glucagon?
    Glucagon is a prescription medicine used:
    • to treat very low blood sugar (severe hypoglycemia) in people with diabetes.
    • to stop stomach movement (gastrointestinal motility inhibitor) in patients receiving radiology exams.
    Who should not use Glucagon?
    Do not use Glucagon if:
    • you have a tumor in the gland on top of your kidneys (adrenal gland) called a pheochromocytoma.
    • you have a tumor in your pancreas called an insulinoma.
    • you are allergic to glucagon or lactose or any of the ingredients in Glucagon. See the end of this Patient Information leaflet for a complete list of ingredients in Glucagon.
    • you have tumors in your pancreas called Glucagonomas because it could cause low blood sugar when used for your radiology exam.
    What should I tell my doctor before using Glucagon?
    Before using Glucagon, tell your doctor about all of your medical conditions, including if you:
    • have kidney problems.
    • have pancreas problems.
    • have not had food or water for a long time (prolonged fasting or starvation).
    • have low blood sugar that does not go away (chronic hypoglycemia).
    • have heart problems.
    • are pregnant or plan to become pregnant. It is not known if Glucagon will harm your unborn baby.
    • are breastfeeding or plan to breastfeed. It is not known if Glucagon passes into your breast milk.
    Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. Glucagon may affect the way other medicines work, and other medicines may affect how Glucagon works. Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.
    How should I use Glucagon?
    • Read the detailed Instructions for Use that come with Glucagon.
    • Use Glucagon exactly as your doctor tells you to.
    • Make sure that you and your family know how to use Glucagon the right way before you need it.
    • Act quickly. Having very low blood sugar for a period of time may be harmful.
    • Call for emergency medical help right after you use Glucagon.
    • If the person does not respond after 15 minutes, another dose may be given, if available.
    • Eat sugar or a sugar sweetened product such as a regular soft drink or fruit juice as soon as you are able to swallow.
    • Tell your doctor each time you use Glucagon. Your doctor may need to change the dose of your diabetes medicines.
    What are the possible side effects of Glucagon?
    Glucagon may cause serious side effects, including:
    • High blood pressure. Glucagon can cause high blood pressure in certain people with tumors in their adrenal glands.
    • Low blood sugar. Glucagon can cause low blood sugar in patients with tumors in their pancreas called insulinomas and Glucagonomas by making too much insulin in their bodies.
    • Serious allergic reactions. Call your doctor or get medical help right away if you have a serious allergic reaction including:
      • rash
      • difficulty breathing
      • low blood pressure
    • High blood sugar. If you receive Glucagon before your radiology exam it can cause high blood sugar. Your doctor will monitor your blood sugar levels during your treatment.
    • Heart problems. If you have heart problems and receive Glucagon before your radiology exam, you may have an increase in your blood pressure and pulse while using Glucagon which could be life threatening.Your doctor will monitor your heart during treatment.
    The most common side effects of Glucagon include:
    • swelling at the injection site
    • redness at the injection site
    • vomiting
    • nausea
    • decreased blood pressure
    • weakness
    • headache
    • dizziness
    • pale skin
    • diarrhea
    • sleepiness or drowsiness
    Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of Glucagon. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
    How should I store Glucagon?
    Before you mix the Glucagon powder and liquid:
    • Store Glucagon at room temperature between 68°F to 77°F (20°C to 25°C) for up to 24 months (2 years).
    • Do not freeze Glucagon.
    • Keep Glucagon in its original package Glucagon and out of light.
    After you mix the Glucagon powder and liquid:
    • Use Glucagon right away.
    • Throw away any unused Glucagon.
    • Glucagon should be clear and colorless. Do not use Glucagon if it is cloudy or if you see particles in the solution.
    Keep Glucagon and all medicines out of the reach of children.
    General information about the safe and effective use of Glucagon:
    Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use Glucagon for a condition for which it was not prescribed. Do not give Glucagon to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about Glucagon that is written for health professionals.
    What are the ingredients in the Glucagon?
    Active Ingredient: Glucagon
    Inactive ingredients: lactose monohydrate and sterile water for reconstitution
    For more information, go to www.fresenius-kabi.com/us or call 1-800-551-7176.
  • INSTRUCTIONS FOR USE

    Instructions for Use

    Glucagon (GLOO-ka-gon)

    for injection, for subcutaneous, intramuscular or intravenous use

    Read this Instructions for Use before you start using Glucagon and each time you get a refill. There may be new information. This information does not take the place of talking with your doctor about your medical condition or treatment. Talk to your doctor or pharmacist if you have any questions about how to use Glucagon.

    Important:

    How should I store Glucagon?

    Before you mix the Glucagon powder and liquid:

    After you mix the Glucagon powder and liquid:

    Supplies you will need for your Glucagon injection (See Figure A):

    Figure A
    Figure A
    Step 1. Using your thumb, flip the orange plastic cap off the Glucagon vial (See Figure B). Figure B
    		Figure B

    Step 2. Pick up the prefilled syringe containing sterile water. Hold the syringe with 1 hand and with your other hand pull the needle cover off the syringe (See Figure C).
    • Do not remove the plastic backstop from the syringe.
    		Figure CFigure C

    Step 3. Pick up the Glucagon vial. Hold the vial of dry powder with 1 hand and with your other hand push the needle of the prefilled syringe through the center of the rubber stopper (See Figure D). Figure DFigure D

    Step 4. Hold the vial and syringe together, with the needle still inserted into the vial. Carefully turn the vial and syringe together right side up. Slowly push the plunger down until the syringe is empty (See Figure E).
    • Do not take the syringe out of the vial.
    		Figure EFigure E

    Step 5. Hold the entire unit (the vial and syringe) in 1 hand and gently shake the vial until the powder is completely dissolved (See Figure F).
    • Do not use if it is cloudy or if you see particles in the solution.
    • Do not take the syringe out of the vial.
    		Figure FFigure F

    Step 6. Firmly hold the vial and syringe together, with the needle still inserted into the vial. Carefully turn the vial and syringe together upside down. Gently pull down on the plunger and slowly withdraw all of the liquid into the syringe (See Figure G).
    • Do not pull the plunger out of the syringe.
    		Figure GFigure G

    Step 7. Keep the needle inside the vial. Check the syringe for air bubbles. If you see bubbles, tap the syringe until the bubbles rise to the top of the syringe (See Figure H). Gently push on the plunger to move only the air bubbles back into the vial. Figure HFigure H

    Step 8. Hold the vial and syringe as shown (See Figure I) Figure IFigure I

    Giving the Glucagon for Injection:
    Step 9. Choose the injection site (See Figure J).
    Common injection sites for Glucagon are upper arms, thighs, or buttocks. Patient does not need to be laying down to administer the medication as long as the common injection sites can be easily accessed.     		Figure JFigure J

    Step 10. With 1 hand gently pinch the skin at the injection site. With your other hand insert the needle into the skin and push the syringe plunger down until the syringe is empty (See Figure K). Figure KFigure K

    After Giving the Glucagon injection:
    Step 11. Pull the needle out of the skin and press on the injection site (See Figure L). Use a gauze pad or cotton ball (not included
    in the kit) if needed to press the injection site to make sure there is no direct contact with the skin.     		Figure LFigure L

    Throw away your used syringe with the needle attached and any Glucagon you did not use. See “How should I dispose of (throw away) used Glucagon prefilled syringes” at the end of these instructions.

    Step 12. Turn the person on their side. When an unconscious person awakens, they may vomit. Turning the person on their side will lessen the chance of choking.

    Step 13. Call for emergency medical help right away. If the person does not respond after 15 minutes,

    another dose may be given, if available.

    Step 14. Feed the person as soon as they are awake and able to swallow.

    Give the person a fast acting source of sugar (such as a regular soft drink or fruit juice) and a long acting source of sugar (such as crackers and cheese or a meat sandwich).

    Step 15. Even if the Glucagon for Injection treatment wakes the person, tell their doctor right away. The doctor should be told whenever a severe drop in blood sugar (hypoglycemia reaction) happens. The person's dose of diabetes medicine may need to be changed.

    Hypoglycemia may happen again after receiving Glucagon for Injection treatment. Early symptoms of hypoglycemia may include:

    • sweating
    • drowsiness
    • dizziness
    • sleep disturbances
    • irregular heartbeat (palpitation)
    • anxiety
    • tremor
    • blurred vision
    • hunger
    • slurred speech
    • restlessness
    • depressed mood
    • tingling in the hands, feet, lips, or tongue
    • irritability
    • abnormal behavior
    • lightheadedness
    • unsteady movement
    • inability to concentrate
    • personality changes
    • headache

    If not treated early, hypoglycemia may worsen and the person may have severe hypoglycemia. Signs of severe hypoglycemia include:

    • confusion
    • unconsciousness
    • seizures
    • death

    How should I dispose of (throw away) Glucagon pre-filled syringes?

    Keep Glucagon and all medicines out of the reach of children.

    This Instructions for Use has been approved by the U.S. Food and Drug Administration. Approved: 09/2019

    The brand names mentioned in this document are the trademarks of their respective owners.

    Manufactured by:
    Fresenius Kabi
    Lake Zurich, IL 60047

    Fresenius Kabi Logo

    www.fresenius-kabi.com/us
    451541

  • PRINCIPAL DISPLAY PANEL

    PACKAGE LABEL - PRINCIPAL DISPLAY - Glucagon 1 mg Vial Label
    509813
    Glucagon for Injection (Synthetic)
    1 mg per vial
    For subcutaneous, intramuscular or intravenous injection.
    Reconstitute with Sterile Water for Injection, USP
    Rx only



    vial


    PACKAGE LABEL - PRINCIPAL DISPLAY - Sterile Water 1 mL Single-Dose Syringe Label
    1 mL Single-Dose Syringe
    Sterile Water for Injection, USP
    For drug diluent use only
    1 mL



    water



    PACKAGE LABEL - PRINCIPAL DISPLAY - Glucagon 1 mg Top of Clamshell
    NDC: 63323-582-82
    Reconstitute with accompanying diluent immediately before use.

    Glucagon Emergency Kit for Low Blood Sugar
    Glucagon for Injection 1 mg per vial
    This Kit contains:

    For subcutaneous, intramuscular or intravenous injection

    Rx only

    clamshell

  • INGREDIENTS AND APPEARANCE
    GLUCAGON  
    glucagon kit
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 63323-582
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 63323-582-821 in 1 KIT; Type 1: Convenience Kit of Co-Package09/09/2019
    Quantity of Parts
    Part #Package QuantityTotal Product Quantity
    Part 11 VIAL, SINGLE-DOSE 1 mL
    Part 21 SYRINGE, GLASS 1 mL
    Part 1 of 2
    GLUCAGON 
    glucagon injection, powder, lyophilized, for solution
    Product Information
    Item Code (Source)NDC: 63323-583
    Route of AdministrationINTRAMUSCULAR, INTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    GLUCAGON HYDROCHLORIDE (UNII: 1H87NVF4DB) (GLUCAGON - UNII:76LA80IG2G) GLUCAGON1 mg  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)  
    HYDROCHLORIC ACID (UNII: QTT17582CB)  
    SODIUM HYDROXIDE (UNII: 55X04QC32I)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 63323-583-131 mL in 1 VIAL, SINGLE-DOSE; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA20184905/08/2015
    Part 2 of 2
    STERILE WATER  
    water injection
    Product Information
    Item Code (Source)NDC: 63323-185
    Route of AdministrationINTRAVENOUS, INTRAMUSCULAR
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    WATER (UNII: 059QF0KO0R) (WATER - UNII:059QF0KO0R) WATER 1 mL  in 1 mL
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 63323-185-821 mL in 1 SYRINGE, GLASS; Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA08840001/16/1984
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA20184909/09/2019
    Labeler - Fresenius Kabi USA, LLC (608775388)
    Establishment
    NameAddressID/FEIBusiness Operations
    Fresenius Kabi USA, LLC023648251MANUFACTURE(63323-582)
    Establishment
    NameAddressID/FEIBusiness Operations
    Fresenius Kabi USA, LLC080381675MANUFACTURE(63323-185)
    • © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.